Benchmark indices close with marginal gains after volatile session; geopolitical tensions impact markets, broader indices ...

Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 Conference Call. At this time, ...

Many economists and Wall Street investors still expect the Fed will reduce rates two or three times this year.

Operator: Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2025 Conference Call. I am George, the Chorus ...

Good day, and welcome to Arcutis Biotherapeutics 2025 first-quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now ...

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The headline numbers for EyePoint Pharmaceuticals (EYPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to ...

Xeris Biopharma Holdings has shown consistent double-digit growth and is expected to continue this trend. Click here to find ...

Here’s our list of the experts and advocates, outside the government, who are playing big roles in Washington’s policy ...

The S&P 500 rose in choppy trading after the Federal Reserve signaled that the risks for an economic slowdown and higher ...

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.The collaboration continues a successful partne ...